Table 2.
Patient and melanoma characteristics at randomization T1 for the study groups
| Characteristics | Total (n = 207) n (%) |
Conventional schedule (n = 103) n (%) |
Experimental schedule (n = 104) n (%) |
p Value | |
|---|---|---|---|---|---|
| Sex | Female | 99 (47.8) | 41 (39.8) | 58 (55.8) | 0.02 |
| Male | 108 (52.2) | 62 (60.2) | 46 (44.2) | ||
| Age (years) | ≤ 55 | 68 (32.9) | 36 (35.0) | 32 (30.8) | 0.46 |
| 56–64 | 62 (29.9) | 33 (32.0) | 29 (27.9) | ||
| 65+ | 77 (37.2) | 34 (33.0) | 43 (41.3) | ||
| Level of education | Primary school | 2 (1.0) | 2 (1.9) | 0 (0.0) | 0.34 |
| Secondary/high | 133 (64.3) | 70 (68.0) | 63 (60.6) | ||
| Diploma | 27 (13.0) | 11 (10.7) | 16 (15.4) | ||
| University | 42 (20.3) | 18 (17.5) | 24 (23.1) | ||
| Unknown | 3 (1.4) | 2 (1.9) | 1 (1.0) | ||
| Relationship status | Without partner | 34 (16.4) | 13 (12.6) | 21 (20.2) | 0.21 |
| With partner | 172 (83.1) | 89 (86.4) | 83 (79.8) | ||
| Unknown | 1 (0.5) | 1 (1.0) | 0 (0.0) | ||
| Daily activities | Employed | 95 (45.9) | 52 (50.5) | 43 (41.3) | 0.41 |
| Not employed | 110 (53.1) | 50 (48.5) | 60 (57.7) | ||
| Unknown | 2 (1.0) | 1 (1.0) | 1 (1.0) | ||
| Presence of comorbidities | No | 119 (57.5) | 60 (58.3) | 59 (56.7) | 0.37 |
| Yes | 86 (41.5) | 43 (41.7) | 43 (41.4) | ||
| Unknown | 2 (1.0) | 0 (0.0) | 2 (1.9) | ||
| Primary melanoma | Head and neck | 34 (16.4) | 15 (14.6) | 19 (18.3) | 0.22 |
| Trunk | 82 (39.6) | 47 (45.6) | 35 (33.7) | ||
| Lower extremity | 45 (21.8) | 23 (22.3) | 22 (21.1) | ||
| Upper extremity | 46 (22.2) | 18 (17.5) | 28 (26.9) | ||
| Breslow thickness | < 1.00 | 47 (22.7) | 21 (20.4) | 26 (25.0) | 0.47 |
| 1.00–2.00 | 103 (49.8) | 55 (53.4) | 48 (46.2) | ||
| 2.01–4.00 | 44 (21.2) | 19 (18.4) | 25 (24.0) | ||
| > 4.00 | 13 (6.3) | 8 (7.8) | 5 (4.8) | ||
| Ulceration | No | 166 (80.2) | 85 (82.5) | 81 (77.9) | 0.40 |
| Yes | 41 (19.8) | 18 (17.5) | 23 (22.1) | ||
| AJCC classification | 1B | 136 (65.7) | 68 (66.0) | 68 (65.4) | 0.97 |
| 2A | 33 (15.9) | 16 (15.5) | 17 (16.3) | ||
| 2B | 33 (15.9) | 16 (15.5) | 17 (16.4) | ||
| 2C | 5 (2.4) | 3 (2.9) | 2 (1.9) |
AJCC American Joint Committee on Cancer